Scholarlink

Objectives <p>Cardiac transthyretin amyloidosis (ATTR CA) has been increasingly recognized as an important heart failure (HF) entity, and cardiac magnetic resonance (CMR) imaging is a mainstay in the clinical evaluation of this disease. However, studies evaluating the prognostic values of longitudinal data in ATTR CA patients with disease-modifying therapies are lacking. We aimed to assess the prognostic significance of serial quantification of extracellular volume (ECV) in ATTR CA patients treated with tafamidis.</p> Materials and methods <p>The present study included ATTR CA patients who received ≥ 3 months of tafamidis treatment and underwent baseline and CMR, including ECV quantification. The primary endpoint was a composite of all-cause mortality, cardiac transplantation, or hospitalization due to HF.</p> Results <p>Between June 2016 and June 2020, 54 patients were included in the present analysis and were representative of a typical ATTR CA cohort (median age: 76.7 years, male participants: 79.6%). The median time on tafamidis before follow-up CMR was 6.0 months (interquartile range (IQR): 6.0–8.3). Participants depicted typical structural changes for ATTR CA patients with markedly elevated ECV (51.4% (IQR: 41.3–57.6), normal range: 20–32%) and myocardial ventricular hypertrophy (intraventricular septum: 19 mm (16.0–22.0), normal range: 5–12 mm). Change of ECV was the only parameter among clinical, laboratory, and CMR parameters that was independently associated with the composite endpoint (HR: 1.077, 95% CI: 1.013–1.145, <i>p</i> = 0.017).</p> Conclusions <p>Change of ECV was the only predictor of adverse outcome among clinical, laboratory, and imaging parameters in our cohort of tafamidis-treated ATTR CA patients.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>What is the prognostic significance of serial ECV quantification in transthyretin amyloidosis patients on tafamidis treatment</i>?</p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>Change of ECV is a strong predictor of a combined endpoint consisting of all-cause mortality, cardiac transplantation, or hospitalization due to HF</i>.</p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>Patients with increasing ECV might potentially benefit from a change in amyloid-specific treatment to a different agent</i>.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Franz Duca,
  • Michael Poledniczek,
  • Christina Kronberger,
  • Christina Binder,
  • René Rettl,
  • Luciana Camuz-Ligios,
  • Hermine Agis,
  • Matthias Koschutnik,
  • Carolina Donà,
  • Roza Badr-Eslam,
  • Dietrich Beitzke,
  • Christian Loewe,
  • Christian Nitsche,
  • Christian Hengstenberg,
  • Johannes Kastner,
  • Jutta Bergler-Klein,
  • Andreas Anselm Kammerlander

摘要

Objectives

Cardiac transthyretin amyloidosis (ATTR CA) has been increasingly recognized as an important heart failure (HF) entity, and cardiac magnetic resonance (CMR) imaging is a mainstay in the clinical evaluation of this disease. However, studies evaluating the prognostic values of longitudinal data in ATTR CA patients with disease-modifying therapies are lacking. We aimed to assess the prognostic significance of serial quantification of extracellular volume (ECV) in ATTR CA patients treated with tafamidis.

Materials and methods

The present study included ATTR CA patients who received ≥ 3 months of tafamidis treatment and underwent baseline and CMR, including ECV quantification. The primary endpoint was a composite of all-cause mortality, cardiac transplantation, or hospitalization due to HF.

Results

Between June 2016 and June 2020, 54 patients were included in the present analysis and were representative of a typical ATTR CA cohort (median age: 76.7 years, male participants: 79.6%). The median time on tafamidis before follow-up CMR was 6.0 months (interquartile range (IQR): 6.0–8.3). Participants depicted typical structural changes for ATTR CA patients with markedly elevated ECV (51.4% (IQR: 41.3–57.6), normal range: 20–32%) and myocardial ventricular hypertrophy (intraventricular septum: 19 mm (16.0–22.0), normal range: 5–12 mm). Change of ECV was the only parameter among clinical, laboratory, and CMR parameters that was independently associated with the composite endpoint (HR: 1.077, 95% CI: 1.013–1.145, p = 0.017).

Conclusions

Change of ECV was the only predictor of adverse outcome among clinical, laboratory, and imaging parameters in our cohort of tafamidis-treated ATTR CA patients.

Key Points

Question What is the prognostic significance of serial ECV quantification in transthyretin amyloidosis patients on tafamidis treatment?

Findings Change of ECV is a strong predictor of a combined endpoint consisting of all-cause mortality, cardiac transplantation, or hospitalization due to HF.

Clinical relevance Patients with increasing ECV might potentially benefit from a change in amyloid-specific treatment to a different agent.

Graphical Abstract